Jim Cramer Says Incyte Has an Amazing Pipeline of Treatments

Jim Cramer does not want to short biotech. These companies are all assessing the Trump effect -- but the biotech companies in our country act as natural pipelines and Incyte (INCY) - Get Report has an amazing pipeline. 

This company has so many different formulations and is red-hot right now, he reasoned, pointing to recent deals with Bristol-Myers Squibb (BMY) - Get Report  and Merck (MRK) - Get Report .

Watch more of Jim Cramer's latest videos:

• Jim Cramer On This Morning's Jobs Report
• Jim Cramer On The Syria Missile Strikes
• Jim Cramer On Oil Volatility
• Jim Cramer On Comcast's New Mobile Service

What will move markets this quarter and how should investors position themselves ahead of time? Jim Cramer sat down with four of TheStreet's top columnists recently to get their views. Click here to listen to his latest Trading Strategies roundtable with them and read their advice for stocks, bonds, forex, tax reform and gold.

This article was written by a staff member of TheStreet.